Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials

Fig. 4

Percent change from baseline in DAS28(CRP) in patients with early RA from a PREMIER and b OPTIMA, or established RA from c DE019 and d ARMADA at week 24/26. P value for difference between response rates for patients treated with ADA+MTX and PBO+MTX. ADA, adalimumab; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us